A bovine cerebral-cortex hydrolysate described in a manufacturing patent. Cerebrolysin, Cortexin and PPK-V are separate preparations.
Research background
A bovine cerebral-cortex hydrolysate described in a manufacturing patent. Cerebrolysin, Cortexin and PPK-V are separate preparations.
What the studies found
Animal research · 2019
Who or what was studiedMale Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis.
Reported finding
Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.
Serial functional testing
Cerebrolysin improved outcomes; Cortexin, Cerebrolysat and Cognistar did not show a comparable significant benefitFigure 1. Neurological severity, adhesive removal and foot-fault testing.
Lesion volume
No significant improvement versus saline in any treatment groupFunctional and histological outcomes are separate.
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
No human outcomes established by the manufacturing patent.
Study methods
Manufacturing disclosure and animal comparison.
Independent replication
Independent replication is not established in the linked sources.
Source access
Original sources and the exact review scope are linked below.
Safety evidence
The linked experiments do not establish a safe human performance regimen.
Open a topic for the evidence assessment.
More findings, background and historyEVIDENCE REVIEW / 6 OCTOBER 2026
Outstanding review questions
Appraise original methods and replication; keep animal and cell findings separate from unestablished human benefit and safety.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
1995 · RU2049472C1 · RU2049472C1: Cerebrolysat manufacturing from bovine brain tissueManufacturing · 10 kDa cutoff; 200 mL final volume
2019 · Blinded rat stroke comparison of four peptide preparationsSerial functional testing: Cerebrolysin improved outcomes; Cortexin, Cerebrolysat and Cognistar did not show a comparable significant benefit
Format: Journal of the Neurological Sciences 398:22–26 · Reviewed: Reported methods, results and evidence limitations
L. Zhang et al. · Journal of the Neurological Sciences 398:22–26
Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.
Findings, study figures and available tables
Reported findings and study design
Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.
Prospective, randomized and blinded comparisons of saline, Cognistar, Cerebrolysat, Cortexin and Cerebrolysin. Serial neurological testing through day 28.
Dose, route and schedule
Daily intraperitoneal doses for ten days starting four hours after occlusion: Cognistar, Cerebrolysat and Cerebrolysin 2.5 mL/kg each, Cortexin 1.7 mg/kg or saline 1 mL per rat. One methods line repeats Cerebrolysin where the abstract and other sections identify Cerebrolysat.
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
A. V. Karyakin, G. S. Vasilyev, V. G. Yusupov, V. N. Melnikov, V. F. Kulagin · RU2049472C1 · patent family 20133945
Two applicant manufacturing examples. No verified comparative clinical data in these examples.
What was checked
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Limitations & review scope
A membrane cutoff is a process parameter. It does not establish the peptide-size distribution or an identity match to PPK-V.
A membrane cutoff is a process parameter. It does not establish the peptide-size distribution or an identity match to PPK-V.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Source checked 2026-11-09. See the review scope above for the material assessed.